Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Pulmonary Arterial Hypertension
NCT06554301Phase 1Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Empagliflozin Arm with Placebo Arm (2 arms). Primary endpoint: 6-minute walking distance at 12 weeks. Started Oct 2024; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06554301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06554301.